Navigation Links
ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
Date:1/30/2013

ng from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the prospects for ANX-188's clinical, regulatory and commercial success in sickle cell disease, including that ANX-188 may be the first FDA-approved product for sickle cell disease in several years, that the orphan-drug designation for poloxamer 188 (purified) is expected provide ANX-188 with seven years of post-approval exclusivity in the U.S., that fast track designation may result in a shortened timeframe for FDA review of a new drug application for ANX-188, and the potential for ANX-188 to be designated a drug for a rare pediatric disease and for ADVENTRX to receive a priority review voucher.  Among the factors that could cause or contribute to material differences between ADVENTRX's actual results and those indicated from the forward-looking statements are risks and uncertainties inherent in ADVENTRX's business, including, but not limited to: the risk that the rate of enrollment in the EPIC study is slower than was anticipated prior to the study's initiation, including as a result of delays in opening study sites and difficulties in recruiting study subjects; the potential for further delays in the commencement or completion of planned clinical studies, including the phase 3 study of ANX-188 in sickle cell disease, including as a result of difficulties in completing manufacturing process development activities, manufacturing sufficient quantities of clinical trial material, meeting applicable regulatory requirements for clinical trial material, meeting applicable requirements of
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
2. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
3. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
4. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
5. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
6. ADVENTRX Announces Appointment Of Chief Medical Officer
7. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
8. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
9. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
10. ADVENTRX Reports Third Quarter 2012 Financial Results
11. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Calif. , Aug. 21, 2014  SI-BONE, Inc. ... device company that pioneered the use of the iFuse ... device indicated for fusion of the sacroiliac (SI) joint, ... published an update to its Lumbar Fusion Medical Policy ... joint fusion procedure.  The policy states that the fusion ...
(Date:8/21/2014)... 21, 2014   Auxilium Pharmaceuticals, Inc. ... company, today announced positive results from a randomized, ... (or CCH) for the treatment of edematous fibrosclerotic ... Phase 2a trial, all three doses of CCH ... an improvement in the appearance of cellulite as ...
(Date:8/20/2014)... Md. , Aug. 20, 2014  The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down meth offenders and make arrests. ... Indiana blocked the sale ...
Breaking Medicine Technology:SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... 22, 2011 Innovative Dialysis Systems, Inc. announces the ... in and around Los Angeles with more options for ... are located in Northridge, Torrance, Carson, and downtown Los ... Reseda Boulevard, was the first of the new centers ...
... 22, 2011     ... catch up   with   their urban counterparts in adopting technology ...   data spill shows risk of online health records . ... IT and its current challenges? Ambitious national healthcare IT programmes and ...
Cached Medicine Technology:Innovative Dialysis Systems, Inc., Announces Opening of Four New Dialysis Facilities in Southern California 2Innovative Dialysis Systems, Inc., Announces Opening of Four New Dialysis Facilities in Southern California 3Innovations in E-Health & Informatics Europe: The Need for a European EHealth Strategy 2
(Date:8/21/2014)... Ohio (PRWEB) August 21, 2014 August ... he took his own life by hanging, likely due ... Sharry Edwards, the foremost BioAcoustic Vocal Profiling investigator, ... offering novel information concerning Williams’ death; hoping to help ... Several issues relevant to Williams’ suicide were proposed in ...
(Date:8/21/2014)... DoudouneCanadienneGoosePasCher.fr, one of the most popular suppliers ... its new selection of Trillium Parkas for 2014. Moreover, ... these fashionable and comfortable items are available at discounted ... last until September 01. , The CEO says ... Canada Goose Trillium Parkas for new and old ...
(Date:8/21/2014)... Los Angeles, CA (PRWEB) August 21, 2014 The ... over the past two decades, according to new insurance industry studies. ... its pet insurance finder to locate affordable plans from all 50 ... pet who pays more than $50 for a routine visit or ... plan for coverage. Every user of the system will be asked ...
(Date:8/21/2014)... An increasing amount of complaints have been ... tax payment is being returned by their financial institution. ... IRS, “tax@irs.gov”, it’s actually a phishing tactic used to ... , While similar scams have been going on for ... is occurring right now. , First, it’s important ...
(Date:8/21/2014)... finding motivation to exercise is a challenge. Thankfully, there are ... Zombies, Run!one of more than 31,000 health and fitness apps ... of apps that use games to increase physical activity. , ... makers looking to cash in to help people get fit. ... to be seen. , "It,s just been assumed that gamified ...
Breaking Medicine News(10 mins):Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Pet Insurance Finder for 50 States Launched at Insurance Website Online 2Health News:Beware Of Phony “Tax Payment Rejected” IRS Emails 2Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2
... , FRIDAY, March 16 (HealthDay News) -- Women who suffer ... likely to miss days at work, a new Dutch study ... could be insomnia, mood swings, irritability, you may be calling ... Lenox Hill Hospital in New York City. Menopause, which ...
... In Vitro Fertilization [IVF] and the related technologies of assisted ... countries as many as 4% of all babies born are ... no doubt be at least one IVF child. Assisted ... BABY-MAKING: What the New Reproductive Treatments Mean for Families and ...
... (March 16, 2012) An international team of researchers from ... Center in Tampa, Fla., have found that the oral BRAF ... trial offered a high rate of response in patients with ... More than 50 percent of the patients in the trial ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, March ... images and smokers, horror stories will be launched next week, ... The essence of the campaign is having real smokers ... to the agency. For the next 12 weeks, the ads ...
... 16 March 2012: Stroke survivors who like art have ... not, according to new research. Patients who appreciated music, painting ... did not. The research was presented at the ... in Copenhagen, Denmark. , Stroke is the third cause ...
... THURSDAY, March 15 (HealthDay News) -- Politicians may want to ... votes, because people appear to prefer candidates with deep voices, ... and women who listened to recordings of high- and low-pitched ... November." Both the male and female participants "elected" the ...
Cached Medicine News:Health News:Menopause May Cost Women Sick Days 2Health News:Menopause May Cost Women Sick Days 3Health News:'Baby-making' 2Health News:Response rate high for some patients with metastatic melanoma treated with vemurafenib 2Health News:CDC Launches Graphic Anti-Smoking Campaign 2Health News:CDC Launches Graphic Anti-Smoking Campaign 3Health News:Art improves stroke survivors' quality of life 2
... 2.0 is a reagent and probe system ... The high throughput plate based system is ... provides a unique approach for RNA detection ... using branched DNA (bDNA) technology. Branched DNA ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
...
Medicine Products: